View clinical trials related to Heart Failure.
Filter by:Open label study of levosimendan; planned comparison for effectiveness and safety to historic matched case controls from participating sites.
Novartis has set up this global Multiple Patient Program (MPP) treatment plan to provide access to life-saving treatment with LCZ696 for patients that were not previously exposed to LCZ696 but have no other option to receive LCZ696 in their country prior to market authorization OR commercial availability, based on local regulatory and legal requirements.